Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Ferric Carboxymaltose in Type 2 Diabetes Mellitus Patients With Iron Deficiency
2011-005224-18Phase 3Completed
- Sponsor
- GWT-TUD
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and iron deficiency anemia (IDA) comparing Ferric carboxymaltose with Placebo (2 arms). Primary endpoint: Change in HbA1c. Started Feb 2012; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
type 2 diabetes mellitus (T2DM)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2011-005224-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005224-18.